Stop-smoking drug wins Health Canada approval
Champix boasts 22 per cent success rate, has no nicotine base
Last Updated: Thursday, January 25, 2007 | 3:54 PM ET
Health
Champix — which was discovered and developed by Pfizer — is one of two quit-smoking drugs that are not designed to replace the nicotine kick that cigarettes offer.
The drug works in two ways — by cutting the pleasure of smoking and reducing the withdrawal symptoms that frequently derail smokers' efforts to quit. If a person smokes while taking Champix, the drug can reduce the sense of satisfaction associated with smoking.
Champix latches on to the same receptors in the brain that nicotine binds to when inhaled in cigarette smoke. The action leads to the release of dopamine in the pleasure centres of the brain. Taking the drug blocks any inhaled nicotine from reinforcing that effect.
Most other stop-smoking drugs are nicotine-replacement therapies, either sold by prescription or over the counter in gum, patch, lozenge, nasal spray or inhaler form. The only other prescription drug sold to help people to quit smoking is Zyban. In the
Champix was approved for sale in
Several studies conducted in
Champix treatment includes 12 weeks of taking the drug as well as smoking-cessation counselling. Pfizer said the drug's possible side-effects include nausea, abnormal dreams, constipation, flatulence and vomiting.
According to Health
No comments:
Post a Comment